Download PDF
Thromb Haemost 1993; 70(02): 357-360
DOI: 10.1055/s-0038-1649580
Scientific and Standardization Committee Communications
Schattauer GmbH Stuttgart

Registry of Clinical Trials of Antithrombotic Drugs in Cancer: Second Report

The Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Subcommittee on Hemostasis and Malignancy
Leo R Zacharski
1   The VA Medical & Regional Office Center, White River Junction, Vermont, and the Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire U.S.A.
,
Maria Benedetta Donati
2   The Istituto di Richerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy
,
Frederick R Rickles
3   The VA Medical Center, Newington, Connecticut, and the Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut, U.S.A.
› Author Affiliations
Further Information

Publication History

Publication Date:
05 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Zacharski LR, Donati MB. Registry of clinical trials of antithrombotic drugs in cancer. Thromb Haemostas 1989; 61: 526-528
    PubMedGoogle Scholar
  • 2 Zacharski LR. Anticoagulation in the treatment of cancer in man. In: Malignancy and the Hemostatic System. Donati M, Davidson J, Garattini S. (eds) Raven Press; New York: 1981: 113-128
  • 3 Maurer LH. Personal communication.
    PubMedGoogle Scholar
  • 4 Lerbeau B. Personal communication.
    PubMedGoogle Scholar
  • 5 Zacharski LR, Henderson WG, Rickies FR, Forman WB, Cornell CJ, Forcier RJ, Edwards RL, Headley E. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of the VA Cooperative Study 75. Cancer 1984; 53: 2046-2052
    CrossrefPubMedGoogle Scholar
  • 6 Chahinian AP, Propert KJ, Ware JH, Zimmer B, Perry MC, Hirsh V, Skarin A, Kopel S. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group. Br J Clin Oncol 1989; 7: 993-1002
    PubMedGoogle Scholar
  • 7 Lebeau B, Chastang CL, Brechot JM. Subcutaneous heparin treatment increases complete reponse rate and overall survival in small cell lung cancer (SCLC). Lung Cancer 1991; 7 (Suppl. 00) 129
    PubMedGoogle Scholar
  • 8 Zacharski LR, Cornell CJ, Haakenson CM, Ballard HS, Crum ED, Johnson GJ, Levine J, Hong WK. Effect of RA-233 (Mopidamole) on survival in carcinoma of the lung and colon: Final report of VA Cooperative Study #188. J Natl Cancer Inst 1988; 80: 9087-9141
    PubMedGoogle Scholar
  • 9 Blaha H, Dierkesmann R, Feuerer W, Gatzemaier U, Geser C, Lemme J, Mall W, Ritscher R. Adjuvante Therapie des nichtkleinzelligen Bronchialkarzinoms mit Mopidamol. Pneumologie 1989; 43: 299-304
    PubMedGoogle Scholar
  • 10 Thun M, Namboodiri M, Heath CJ. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1595-1596
    PubMedGoogle Scholar
  • 11 Rosenberg L, Palmer J, Zauber A, Warshauer M, Stolley P, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991; 83: 355-358
    CrossrefPubMedGoogle Scholar
  • 12 Kune G, Kune S, Watson L. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399-4404
    PubMedGoogle Scholar
  • 13 Paganini-Hill A, Chao A, Ross R, Henderson B. Aspirin use and chronic diseases – a cohort study in the elderly. Br Med J 1989; 299: 1247-1250
    CrossrefPubMedGoogle Scholar
  • 14 Labayle D, Fischer D, Vielh P. Sulindac causes regression of rectal polyp in familial adenomatous polyposis. Gastroenterology 1991; 101: 635-639
    CrossrefPubMedGoogle Scholar
  • 15 Waddell W, Ganser G, Cerise E, Loughry R. Sulindac for polyposis of the colon. Am J Surg 1989; 157: 175-179
    CrossrefPubMedGoogle Scholar
  • 16 Rigan J, Pique J, Rubio E, Planas R, Tarrech J, Bordas J. Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991; 115: 952-954
    CrossrefPubMedGoogle Scholar
  • 17 Baron J, Greenberg E. Could aspirin really prevent colon cancer?. N Engl J Med 1991; 325: 1644-1645
    CrossrefPubMedGoogle Scholar
  • 18 Rickies FR, Hancock WW, Edwards RL, Zacharski LR. Antimetastaic agents. I. Role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulants and/or antiplatelet drugs in cancer treatment. Semin Thromb Hemostas 1988; 14: 88-94
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Zacharski L, Memoli VA, Costantini V, Wojtukiewicz MZ, Ornstein DL. Clotting factors in tumor tissue: Implications for cancer therapy. Blood Coag Fibrinolys 1990; 1: 71-78
    PubMedGoogle Scholar
  • 20 Zacharski LR, Wojtukiewcz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Hemostas Thromb 1992; 18: 104-116
    PubMedGoogle Scholar
  • 21 Calvo PA, Harguindey SS, Aparicio LA, Dy C, Gil A, Rocha E. Urokinase and combination chemotherapy for treatment of small cell carcinoma of the lung. Cancer Treat Symp 1985; 2: 105-108
    PubMedGoogle Scholar
  • 22 Calvo FA, Santos M, Hidalgo OF. Urokinase-combination chemotherapy in small cell lung cancer: A phase II study. Proc ASCO 1990; 9: 237
    PubMedGoogle Scholar
  • 23 Calvo FA, Hidalgo OF, Gonzalez F, Rebollo J, Martin AlgarraS, Ortiz de UrbinaD, Brugarolas A. Urokinase combination chemotherapy in small cell carcinoma of the lung. A phase II study. Cancer 1992; 70: 2624-2630
    CrossrefPubMedGoogle Scholar
  • 24 Monden T, Morimoto H, Shimano T, Yagyu T, Murotani M, Nagaola H, Kawasaki Y, Kobayashi T. Use of fibrinogen to enhance the antitumor effect of OK-432. Cancer 1992; 69: 636-642
    CrossrefPubMedGoogle Scholar
  • 25 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Indirect activation of blood coagulation in colon cancer. Thromb Haemostas 1989; 62: 1062-1066
    PubMedGoogle Scholar
  • 26 Astedt B, Glifberg I, Mattson W, Trope C. Arrest of growth of ovarian tumor by tranexamic acid. J Am Med Assoc 1977; 238: 154-155
    CrossrefPubMedGoogle Scholar
  • 27 Astedt B. Adjuvant treatment of ovarian carcinoma with tranexamic acid. J Clin Pathol 1980; 3 (Suppl. 00) 74-76
    PubMedGoogle Scholar
  • 28 Kikuchi Y, Kizawa I, Oomori K, Matsuda M, Kato K. Adjuvant effects of tranexamic acid to chemotherapy in ovarian cancer patients with large amounts of ascites. Acta Obstet Gynecol Scand 1986; 65: 453-456
    CrossrefPubMedGoogle Scholar
  • 29 Serdengecti S, Buyuskunal E, Molinas N, Demirelli F, Berkards N, Eyuboglu H, Derman U, Berkarda B. Overall survival results of nonsmall cell lung cancer patients: chemotherapy alone versus chemotherapy with combined immunomodulation. Chemiotherapia 1988; 7: 122-126
    PubMedGoogle Scholar
  • 30 Ornstein D, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Hunt J, Rousseau SM, Stump DC. Coexistent macrophage procoagulant and tumor cell plasminogen activator in adenocarcinoma and squamous cell carcinoma of the lung. Cancer 1991; 68: 1061-1067
    CrossrefPubMedGoogle Scholar
  • 31 Hansen R, Schuetz M, Vukelich M, Blake D, Anderson T. A phase II study of 5-fluorouracil (5 FU) infusion interferon alpha, and dipyridamole in advanced colorectal cancer. Proc Am Soc Clin Oncol 1991; 10: 154
    PubMedGoogle Scholar
  • 32 Zaniboni A, Marpicati P, Simoncini E, Montini E, Meriggi F, Arcangeli G, Bonera F, Braga M, Ragni F, Marini G. Fluorouracil, high-dose folinic acid, low dose alpha-2b interferon and dipyridamole in the treatment of advanced colorectal cancer. A pilot study. J Chemother 1991; 3: 180-182
    CrossrefPubMedGoogle Scholar
  • 33 Migeod F, Gerlach D, Kress M, Hoffman W, Farroukh R, Sieber S. Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyridamole and mitomycin C. Onkologie 1988; 11 (Suppl. 02) 14-20
    PubMedGoogle Scholar
  • 34 Wereldsma J, Bruggink E, Meijer W, Roukema J, van Putten W. Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Cancer 1990; 65: 425-432
    CrossrefPubMedGoogle Scholar
  • 35 Daly L. The first international urokinase/warfarin trial in colorectal cancer. Clin Exp Metast 1991; 9: 3-11
    CrossrefPubMedGoogle Scholar
  • 36 Lipton A, Harvey H, Walker BRD, Valdivia D, Barnes S, Gordon R, Whitehershey D, Bartholomew MJ, Warzawski N, Antle CE. Chemotherapy plus RA-233 in the treatment of oat-cell lung cancer. Am J Clin Oncol – Cancer Clin Trials 1989; 12: 259-263
    PubMedGoogle Scholar
  • 37 Nieminen U, Kauppila A, Gronroos M, Kuoppala T, Vayrynen M. Placebo-controlled study on the efficacy of the pyrimido-pyrmidine derivative RA-233 in ovarian cancer. Gynecol Oncol 1990; 36: 226-231
    CrossrefPubMedGoogle Scholar
  • 38 Daniel F, Rao D, Tyrrell C. A pilot study of stanozolol for advanced breast carcinoma. Cancer 1991; 67: 2966-2968
    CrossrefPubMedGoogle Scholar
  • 39 Waddell WR, Kirsch WM. Testolactone, salindac, warfarin, and vitamin K1 for unresectable desmoid tumors. Am J Surg 1991; 161: 416-421
    CrossrefPubMedGoogle Scholar
  • 40 Israel L, Breau J, Morere J, Boaziz C. Anticancer effects of oral and intratumoral prostaglandin inhibitors. In: Ercosanoids and Other Bioactive Lipids in Cancer and Radiation Injury. Honn K, Marnett L, Nigam S, Walden TJ. (eds) Klewer; Boston, IL: 1991: 487-488
  • 41 Cregan ET, Twito DI, Johansson SL, Schaid DJ, Johnson PS, Flaum MA, Buroker TT, Geeraers LH, Veeder MH, Gesme Jr DH. et al. A randomized prospective assessment of recombinant leukocyte. A human interferon with or without aspirin in advanced renal adenocarcinoma. J Clin Oncol 1991; 12: 2104-2109
    PubMedGoogle Scholar
  • 42 Murphy B, Rynard S, Pennington K, Grosh W, Loehrer PJ. A phase II trial of vinblastine (VLB) plus dipyridamole (DP) in advanced renal cell carcinoma (RCC): A Hoosier oncology group study. Proc Am Soc Clin Oncol 1991; 10: 176
    PubMedGoogle Scholar
  • 43 Isacoff WH, Jacobs AD, Taylor O. Continuous infusion (CI) 5-fluorouracil (5-FU) combined with calcium leucovrin (LV), mitomycin-C (mito-C), and dipyridamole (D) in advanced colorectal carcinoma. Proc Am Soc Clin Oncol 1991; 10: 154
    PubMedGoogle Scholar
  • 44 Kohne-Wompner CH, Wilke H, Weiss W, Hiddemann W, Gropp C, Schmitz-Hubner U, Zohrman HP, Bodenstein H, Preusser P, Urbanitz D, Hotz J, Preiss J, Knuth A, Schwark J, Bade J, Kohler B, Schmoll HJ. 5-FU, folinic acid (FA) +/- dipyridamole (D) in advanced and progressive colorectal cancer (CC) – a randomized multicenter phase II trial. Proc Am Soc Clin Oncol 1990; 10: 123
    PubMedGoogle Scholar
  • 45 Higano CS, Livingston RB. Oral dipyridamole and methotrexate in human solid tumors: a toxicity trial. Cancer Chemother Pharmacol 1989; 23: 259-262
    CrossrefPubMedGoogle Scholar
  • 46 Wilson JK, Fischer PH, Tutsch K, Alberti D, Simon K, Hamilton RD, Bruggink J, Koeller JM, Tormey DC, Earhart RH. Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. Cancer Res 1988; 48: 5585-5590
    PubMedGoogle Scholar
  • 47 Budd GT, Jayaraj A, Grabowski D, Adelstein D, Bauer L, Boyett J, Bukowski R, Murthy S, Weick J. Phase I trial of dipyridamole with 5-fluorouracil and folinic acid. Cancer Res 1990; 50: 7206-7211
    PubMedGoogle Scholar
  • 48 Sakaguchi Y, Maehara Y, Emi Y, Kusumoto T, Kohnoe S, Sugimachi K. Dipyridamole combination chemotherapy can be used safely in treating gastic cancer patients. Anticancer Drugs 1991; 2: 139-143
    CrossrefPubMedGoogle Scholar
  • 49 Fountzilas G, Zisiadis A, Kosmidis P, Basdanis G, Makrantonakis P, Paspatis A, Tsavdaridis D, Tsavaris N, Aletras O, Tourkantonis A. High-dose leucovarin, fluorouracil and oral dipyridamole in the treatment of advanced colorectal cancer. Anticancer Res 1991; 11: 865-868
    PubMedGoogle Scholar
  • 50 Tsavaris N, Zinelis A, Karvorinis N, Beldecos D, Mylonacis N, Zamanis N, Bacoyannis C, Valilis P, Antonopoulos A, Kosmidis P. Multimodal biochemical modulation of 5-fluorouracil activity in advanced colorectal cancer with 5-fluorouracil, folinic acid and dipyridamole. J Chemother 1990; 2: 123-126
    CrossrefPubMedGoogle Scholar
  • 51 Kobayaski T, Sasaki T, Ibuka T, Imai K, Monma K, Sakaki N, Tabata I, Ishirvata J, Onozawa Y, Ohno T. Sequential MTX and 5-FU therapy of gastric cancer with systemic bone metastasis and disseminated intravascular coagulation. Gan To Kagaku Ryoho 1992; 19: 69-74
    PubMedGoogle Scholar